Your browser doesn't support javascript.
loading
Effects of a live versus heat-inactivated probiotic Bifidobacterium spp in preterm infants: a randomised clinical trial.
Athalye-Jape, Gayatri; Esvaran, Meera; Patole, Sanjay; Nathan, Elizabeth A; Doherty, Dorota A; Sim, Edric; Chandrasekaran, Lakshmi; Kok, Chooi; Schuster, Stephan; Conway, Patricia.
Afiliación
  • Athalye-Jape G; Neonatal Directorate, King Edward Memorial Hospital for Women Perth, Subiaco, Western Australia, Australia Gayatri.Jape@health.wa.gov.au.
  • Esvaran M; University of Western Australia, Perth, Western Australia, Australia.
  • Patole S; University of New South Wales, Sydney, New South Wales, Australia.
  • Nathan EA; Neonatology, King Edward Memorial Hospital, Perth, Western Australia, Australia.
  • Doherty DA; Neonatology, Centre for Neonatal Research and Education, Perth, Western Australia, Australia.
  • Sim E; Women and Infants Research Foundation, Western Australia, Australia, Australia.
  • Chandrasekaran L; School of Women's and Infants' Health, University of Western Australia, Perth, Western Australia, Australia.
  • Kok C; Nanyang Technological University, Singapore.
  • Schuster S; Nanyang Technological University, Singapore.
  • Conway P; Neonatal Directorate, King Edward Memorial Hospital for Women Perth, Subiaco, Western Australia, Australia.
Arch Dis Child Fetal Neonatal Ed ; 2024 Aug 17.
Article en En | MEDLINE | ID: mdl-39153842
ABSTRACT

BACKGROUND:

Heat-inactivated probiotics (HPs) may provide an effective alternative to live probiotics (P) by avoiding their risks (eg, probiotic sepsis) while retaining the benefits. We assessed the safety and efficacy of a HP in very preterm (VP gestation <32 weeks) infants.

METHODS:

VP infants were randomly allocated to receive a HP or P mixture (Bifidobacterium breve M-16V, Bifidobacterium longum subsp. infantis M-63, Bifidobacterium longum subsp. longum BB536, total 3×109 CFU/day) assuring blinding. Primary outcome was faecal calprotectin (FCP) levels were compared after 3 weeks of supplementation. Secondary outcomes included faecal microbiota and short chain fatty acid (SCFA) levels.

RESULTS:

86 VP infants were randomised to HP or P group (n=43 each). Total FCP and SCFA were comparable between HP and P groups within 7 days (T1) and between day 21 and 28 (T2) after supplementation. At T2, median (range) FCP was 75 (8-563) in the HP group and 80 (21-277) in the P group (p=0.71). Propionate was significantly raised in both groups, while butyrate was significantly raised in the HP group (all p<0.01). Bacterial richness and diversity increased but was comparable between HP and P (p>0.05). Beta diversity showed similar community structures in both groups (all p>0.05). Changes in faecal Actinobacteria, Bacteroidetes and Bifidobacteriacae levels were comparable in both groups at T1 and T2. There was no probiotic sepsis.

CONCLUSIONS:

HP was safe and showed no significant difference in FCP as compared with a live probiotic. Adequately powered trials are needed to assess the effects of HP on clinically significant outcomes in preterm infants. TRIAL REGISTRATION NUMBER ACTRN12618000489291.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Arch Dis Child Fetal Neonatal Ed Asunto de la revista: PEDIATRIA / PERINATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Arch Dis Child Fetal Neonatal Ed Asunto de la revista: PEDIATRIA / PERINATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Reino Unido